ACD 856
Alternative Names: ACD-856Latest Information Update: 13 Oct 2025
At a glance
- Originator AlzeCure
- Class Antidementias; Antidepressants; Neuroprotectants; Sleep disorder therapies; Small molecules; Triazines
- Mechanism of Action TrkA receptor agonists; TrkB receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cognition disorders
Highest Development Phases
- Phase I Alzheimer's disease; Depressive disorders; Parkinson's disease; Sleep disorders; Traumatic brain injuries
Most Recent Events
- 13 Oct 2025 Phase-I clinical trials in Depressive disorders (In volunteers) in Sweden (unspecified route) (AlzeCure Pharma pipeline, October 2025)
- 13 Oct 2025 Phase-I clinical trials in Parkinson's disease (In volunteers) in Sweden (PO) (AlzeCure Pharma pipeline, October 2025)
- 13 Oct 2025 Phase-I clinical trials in Sleep disorders (In volunteers) in Sweden (unspecified route) (AlzeCure Pharma pipeline, October 2025)